Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters

Abstract

AbstractIntroductionAdjuvant (A) multiagent chemotherapy (MC) is the standard of care for patients with pancreatic adenocarcinoma (PDAC). Tolerating MC following a morbid operation may be difficult, thus neoadjuvant (NA) treatment is preferable. This study examined how the timing of chemotherapy was related to the regimen given and ultimately the overall survival (OS).MethodsThe National Cancer Database was queried from 2006 to 2017 for nonmetastatic PDAC patients who underwent surgical resection and received MC or single‐agent chemotherapy (SC) pre‐ or postresection. Predictors of receiving MC were determined using multivariable logistic regression. Five‐year OS was evaluated using the Kaplan–Meier and Cox proportional hazards model.ResultsA total of 12,440 patients (NA SC, n = 663; NA MC, n = 2313; A SC, n = 6152; A MC, n = 3312) were included. MC utilization increased from 2006–2010 to 2011–2017 (33.1%–49.7%; odds ratio [OR]: 0.59; p < 0.001). Younger age, fewer comorbidities, higher clinical stage, and larger tumor size were all associated with receipt of MC (all p < 0.001), but NA treatment was the greatest predictor (OR 5.18; 95% confidence interval [CI]: 4.63–5.80; p < 0.001). MC was associated with increased median 5‐year OS (26.0 vs. 23.9 months; hazard ratio [HR]: 0.92; 95% CI: 0.88–0.96) and NA MC was associated with the highest survival (28.2 months) compared to NA SC (23.3 months), A SC (24.0 months), and A MC (24.6 months; p < 0.001).ConclusionUse and timing of MC contribute to OS in PDAC with an improved 5‐year OS compared to SC. The greatest predictor of receiving MC was being given as NA therapy and the greatest survival benefit was the NA MC subgroup. Randomized studies evaluating the timing of effective MC in PDAC are needed.